RCN and NHS England briefing on best value biological medicines for specialist nurses

NHS England has worked in partnership with the Royal College of Nursing (RCN) to produce a briefing for specialist nurses on best value biological medicines, with a particular focus on adalimumab, biological versions of which are scheduled to be available on a framework agreement on behalf of the NHS from 1 December 2018.

This briefing covers the role of specialist nurses in supporting patients who switch to best value biological medicines. It covers the key areas such as supporting patients to understand their medicines and treatment options, the importance of shared decision making and the safety and efficacy of biological medicines. It also includes links to further resources such as the patient Frequently Asked Questions, a template patient letter and an article for patient newsletters.

AdalimumabBiosimilar medicineRMOC medicines optimisation recommendations and resourcesRMOC recommendations and resources

Attachments